Treatment for HER2-Negative Breast Cancer with Germline BRCA Mutation Granted FDA Approval – Drug for nerve pain boosts high for opioid abusers.

16513-PHARMACY BOARD-standard-041216Aabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Treatment for HER2-Negative Breast Cancer with Germline BRCA Mutation Granted FDA Approval – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

Officials with the FDA have approved talazoparib (Talzenna, Pfizer) for the treatment of HER2-negative locally advanced or metastatic breast cancer with germline BRCA (gBRCA) mutations, according to a press release.

Talazoparib, a poly ADP-ribose polymerase (PARP) inhibitor, is indicated for patients with known deleterious or suspected deleterious gBRCA-mutated breast cancer who are selected for the therapy based on an FDA-approved companion diagnostic.

As a dual-mechanism PARP inhibitor, talazoparib both inhibits and traps the PARP enzyme, which may lead to heightened cell death, according to Pfizer.

CLICK HERE FOR CONTINUE READING

This entry was posted in Pharmacist and tagged , , , . Bookmark the permalink.

Comments are closed.